Biosimilar

Senior Sun Pharma executives speak on a two-pronged strategy for the China market, beginning R&D of biosimilar products, and more

Indian drugmaker Biocon Ltd is in talks with generic drugmaker Mylan for a merger of their biosimilar businesses, a report said

Data shows while the overall biosimilars category has clocked a 10.3% value compound annual growth rate (CAGR) over the past few years, the market size for the top molecule has more than doubled

Weak sentiments, rich valuations will weigh on the scrip in near term

Biosimilars are made from living cells and are far more complex and expensive to manufacture than generic drugs